Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.5 GBX | 0.00% | -1.35% | -12.05% |
Mar. 04 | Beximco names Iqbal Ahmed as managing director | AN |
Jan. 30 | Beximco Pharmaceuticals to strengthen portfolio as interim profit up | AN |
Sales 2024 * | 44.55B 405M | Sales 2025 * | 50.49B 459M | Capitalization | 51.79B 471M |
---|---|---|---|---|---|
Net income 2024 * | 5.13B 46.67M | Net income 2025 * | 6B 54.56M | EV / Sales 2024 * | 1.3 x |
Net Debt 2024 * | 5.99B 54.5M | Net Debt 2025 * | 884M 8.04M | EV / Sales 2025 * | 1.04 x |
P/E ratio 2024 * |
9.44
x | P/E ratio 2025 * |
7.69
x | Employees | 5,700 |
Yield 2024 * |
3.45% | Yield 2025 * |
4.31% | Free-Float | 76.68% |
1 week | -1.35% | ||
Current month | -6.41% | ||
1 month | -6.41% | ||
3 months | +4.29% | ||
6 months | -5.19% | ||
Current year | -12.05% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 61 | 89-12-31 | |
Chief Tech/Sci/R&D Officer | - | - | |
Selina Akter
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | - | 75-12-31 | |
Founder | - | 75-12-31 | |
Iqbal Ahmed
CEO | Chief Executive Officer | - | 84-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 36.5 | 0.00% | 105,000 |
24-04-25 | 36.5 | 0.00% | 5,473 |
24-04-24 | 36.5 | -1.35% | 10,477 |
24-04-23 | 37 | 0.00% | 23,201 |
24-04-22 | 37 | 0.00% | 0 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- BXPHARMA Stock
- BXP Stock